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Introduction
Extensive research has established the role of 
lifestyle, diet, and genetic variations in the 
etiology of type 2 diabetes (T2D) (Qi et al. 
2008). Meanwhile, emerging evidence has 
led to a novel hypothesis that some of these 
chemicals, such as bisphenol A (BPA) and 
phthalates, may also be related to the rising 
epidemics of obesity and T2D (Casals-Casas 
and Desvergne 2011). Both classes of chemi-
cals are produced in large quantities world-
wide and have wide industrial applications 
(Casals-Casas and Desvergne 2011; Hauser 
and Calafat 2005) and can be detected ubiq-
uitously in human urines (Calafat et al. 2008; 
Silva et al. 2004).
Animal experiments suggest that, in addi-
tion to its well-known estrogenic effects, BPA 
may also interfere with multiple pathways 
related to T2D, including impaired beta-cell 
function (Alonso-Magdalena et al. 2006), 
liver dysfunction (Bindhumol et al. 2003; 
Nakagawa and Tayama 2000), dysregula-
tion of glucose metabolism and adipo  nectin 
release in adipocytes (Ben-Jonathan et al. 
2009; Hugo et al. 2008), and disruption 
of thyroid hormone functions (Moriyama 
et al. 2002). Experimental evidence suggests 
that phthalates may also affect the liver and 
interfere with adipocyte biology and glucose 
metabolism through effects on peroxisome 
proliferator-activated receptors (PPARs) 
(Desvergne et al. 2009). Despite the accumu-
lation of evidence from animal studies, evi-
dence among humans for associations of BPA 
and phthalates with T2D has been limited to 
cross-sectional studies, with mixed findings 
(James-Todd et al. 2012; LaKind et al. 2012; 
Lang et al. 2008; Lind et al. 2012b; Ning 
et al. 2011; Shankar and Teppala 2011; Silver 
et al. 2011; Svensson et al. 2011).
Therefore, we analyzed data from two pro-
spective cohort studies among U.S. women, 
the Nurses’ Health Study (NHS) and the 
NHSII, to evaluate associations between 
urinary concentrations of BPA and phthal-
ate metabolites and incident T2D. The 
non-overlapping age distributions between 
the two cohorts allowed us to examine these 
associations among different age groups and 
by menopausal status. Based on experimental 
data suggesting that BPA interferes with beta-
cell functions by activating estrogen recep-
tors (Alonso-Magdalena et al. 2006; Nadal 
et al. 2009; Soriano et al. 2012), we hypothe-
sized that associations with BPA would be 
stronger in premenopausal women than in 
 postmenopausal  women.
Methods
Study population. The NHS was established in 
1976 when 121,700 female registered nurses 
30–55 years of age were enrolled, whereas in 
1989 the younger counterpart NHSII cohort 
was initiated among a total of 116,430 female 
registered nurses 25–42 years of age. A total 
of 18,743 NHS participants 53–79 years 
of age provided blood and urine samples in 
2000–2002. In 1996–2001, blood and urine 
samples were collected from 29,611 NHSII 
participants 32–52 years of age. Urine samples 
were collected without preservative in a poly-
propylene container and returned to a central 
biorepository via overnight courier with an ice-
pack, where they were processed immediately 
upon arrival and aliquoted into polypropylene 
cryovials, which were stored in the vapor phase 
of liquid nitrogen freezers at ≤ –130°C. In 
both cohorts, a high follow-up rate of > 90% 
was maintained among participants who 
  provided urine samples.
Assessment of covariates. NHS partici-
pants responded to a questionnaire inquiring 
about body weight, height, demographic and 
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Background: Prospective evidence regarding associations for exposures to bisphenol A (BPA) and 
phthalates with type 2 diabetes (T2D) is lacking.
oBjective: We prospectively examined urinary concentrations of BPA and phthalate metabolites 
with T2D risk.
Methods: We measured BPA and eight major phthalate metabolites among 971 incident T2D 
case–control pairs from the Nurses’ Health Study (NHS) (mean age, 65.6 years) and NHSII (mean 
age, 45.6 years).
results: In the NHSII, BPA levels were not associated with incident T2D in multivariate-adjusted 
analysis until body mass index was adjusted: odds ratio (OR) comparing extreme BPA quartiles 
increased from 1.40 (95% CI: 0.91, 2.15) to 2.08 (95% CI: 1.17, 3.69; ptrend = 0.02) with such an 
adjustment. In contrast, BPA concentrations were not associated with T2D in the NHS (OR = 0.81; 
95% CI: 0.48, 1.38; ptrend = 0.45). Likewise, urinary concentrations of total phthalate metabolites 
were associated with T2D in the NHSII (OR comparing extreme quartiles = 2.14; 95% CI: 1.19, 
3.85; ptrend = 0.02), but not in the NHS (OR = 0.87; 95% CI: 0.49, 1.53; ptrend = 0.29). Summed 
metabolites of butyl phthalates or di-(2-ethylhexyl) phthalates were significantly associated with 
T2D only in the NHSII; ORs comparing extreme quartiles were 3.16 (95% CI: 1.68, 5.95; 
ptrend = 0.0002) and 1.91 (95% CI: 1.04, 3.49; ptrend = 0.20), respectively.
conclusions: These results suggest that BPA and phthalate exposures may be associated with the 
risk of T2D among middle-aged, but not older, women. The divergent findings between the two 
cohorts might be explained by menopausal status or simply by chance. Clearly, these results need to 
be interpreted with caution and should be replicated in future studies, ideally with multiple urine 
samples collected prospectively to improve the measurement of these exposures with short half-lives.
citation: Sun Q, Cornelis MC, Townsend MK, Tobias DK, Eliassen AH, Franke AA, Hauser R, 
Hu FB. 2014. Association of urinary concentrations of bisphenol A and phthalate metabolites with 
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lifestyle information, and medical history at 
study baseline. Similar follow-up question-
naires have been administered biennially since 
baseline to update these variables. In 1984, 
1986, and every 4 years thereafter, a validated 
food frequency questionnaire (FFQ) has been 
used to assess participants’ usual diet. In the 
NHSII, questionnaires similar to those used 
in the NHS are sent biennially to update life-
style and health-related characteristics. The 
FFQ was first administered in 1991 and is 
updated every 4 years in the NHSII. Based on 
the FFQ, we derived a score of the Alternative 
Healthy Eating Index (AHEI), an indica-
tor of adherence to healthy eating behavior 
(McCullough et al. 2002). Of note, the FFQs 
did not inquire about any food packaging 
information. Information on cigarette smok-
ing, physical activity, family history of dia-
betes, menopausal status, oral contraceptive 
use, hormone replacement therapy, and the 
history of hypertension or hypercholesterol-
emia were also assessed in the questionnaires 
at baseline and during follow-up. In the ques-
tionnaires, participants were asked about the 
average time per week in the past year spent 
on leisure-time physical activities. Based on 
this information, we calculated energy expen-
diture in metabolic equivalent tasks (METs) 
measured in hours per week.
Ascertainment of T2D. At baseline and 
on all biennial follow-up questionnaires, 
participants were asked whether they had 
received a physician-diagnosis of diabetes. 
Those reporting a diabetes diagnosis were 
sent a supplementary questionnaire (Manson 
et al. 1991) regarding any symptoms, diag-
nostic tests, and treatment. We used one of 
the following American Diabetes Association 
1998 criteria to confirm self-reported T2D 
diagnosis: a) an elevated glucose concentra-
tion (fasting plasma glucose ≥ 7.0 mmol/L, 
random plasma glucose ≥ 11.1 mmol/L, 
or plasma glucose ≥ 11.1 mmol/L after an 
oral glucose load) and at least one symptom 
(excessive thirst, polyuria, weight loss, or hun-
ger) related to diabetes; b) no symptoms, but 
elevated glucose concentrations on two sepa-
rate occasions; or c) treatment with insulin or 
oral hypo  glycemic medication. The accuracy 
of self-reported diagnosis of T2D has been 
demonstrated in a validation study (Manson 
et al. 1991), in which a blinded endocrinolo-
gist confirmed the diagnosis of diabetes by 
reviewing medical records of 61 of 62 NHS 
participants who responded to the supple-
mentary questionnaire. Only confirmed T2D 
cases were included in the present study in 
order to minimize possible misclassification.
Nested case–control study. We prospec-
tively identified and confirmed 971 T2D 
cases (NHS, 394; NHSII, 577) through June 
2008 (NHS) or June 2007 (NHSII) among 
participants who provided first morning urine 
samples and were free of T2D, cardiovascular 
disease, and major cancers except nonmela-
noma skin cancer at sample collection. Using 
the risk–set sampling scheme, we randomly 
selected one control for each case from among 
the women who remained free of T2D at the 
case’s date of diagnosis (Prentice and Breslow 
1978). We matched cases and controls for 
age at urine sample collection (± 1 year), date 
(± 3 months)/time (first morning or not) of 
sample collection, ethnicity (white or other), 
fasting status when blood was drawn (≥ 8 hr 
or not), and menopausal status (yes, no) and 
hormone replacement therapy use (yes, no) 
at sample collection (NHSII only). T2D 
cases diagnosed within the first year since 
urine sample collection were excluded from 
selection in order to reduce the potential for 
reverse causa  tion bias.
The study protocol was approved by the 
institutional review board of the Brigham and 
Women’s Hospital and the Human Subjects 
Committee Review Board of Harvard 
School of Public Health. Informed consent 
was provided by all participants involved in 
this research.
Laboratory measurements. Urinary 
concentrations of BPA and eight phthalate 
metabolites [mono-(2-ethylhexyl) phthalate 
(MEHP), mono-(2-ethyl-5-hydroxyhexyl) 
phthalate (MEHHP), mono(2-ethyl-
5-carboxypentyl) phthalate (MECPP), mono-
(2-ethyl-5-oxohexyl) phthalate (MEOHP), 
monobutyl phthalate (MBP), mono-isobutyl 
phthalate (MiBP), mono  benzyl phthalate 
(MBzP), monoethyl phthalate (MEP), and 
phthalic acid] were measured using established 
methods with modifications (Fox et al. 2011; 
Kato et al. 2005) (see Supplemental Material, 
“Laboratory measurements,” pp. 2–3, for 
complete details). Briefly, samples were mixed 
with isotopically-labeled phthalate metabolites 
and BPA and treated with β-glucuronidase 
and sulfatase. Urinary concentrations of 
phthalate metabolites were measured by 
orbitrap-liquid chromatography–mass spec-
trometry (LCMS) (model Exactive; Thermo 
Electron, Waltham, MA), and BPA concen-
trations were measured by tandem-LCMS 
(model TSQ Ultra; Thermo Electron) at 
A. Franke’s laboratory at the University of 
Hawaii Cancer Center in 2012. Of note in 
the NHS only, because of technical reasons, 
concentrations of phthalic acid were not avail-
able for 144 case–control pairs, and only com-
bined concentrations of MBP and MiBP were 
available. We also measured urinary creatinine 
levels using a Roche-Cobas MiraPlus clinical 
chemistry autoanalyzer (Roche Diagnostics, 
Indianapolis, IN) with a kit from Randox 
Laboratories (Crumlin, UK). Lastly, In the 
NHS we measured two liver enzymes [alanine 
transaminase (ALT) and γ-glutamyl trans-
peptidase (GGT)] using a direct enzymatic 
colorimetric assay, performed on the Roche 
P Modular system (Roche Diagnostics). In 
addition, fetuin-A levels were measured by 
an enzyme immunoassay from R&D Systems 
(Minneapolis, MN) in the NHS (Sun 
et al. 2013).
Quality control procedures. Each pair 
of matched case–control urine samples was 
shipped in the same batch and analyzed in 
the same run. Within each batch, samples 
were assayed by the same technician in a ran-
dom sequence under identical conditions. 
Duplicates of blinded quality control samples 
(n = 82 for NHS; 116 for NHSII) were run 
along with the case–control samples to moni-
tor the quality of these assays. We calculated 
intra-assay coefficients of variation (CVs) 
based on the measurements of these sam-
ples. The average CVs were < 10% for most 
metabolites (including creatinine), except for 
MEHP (NHS 11.4%, NHSII 10.0%) and 
BPA (NHS 11.5%, NHSII 13.0%).
Within-person stability of metabolites. We 
measured BPA and phthalates in two urine 
samples collected 1–3 years apart from a sepa-
rate sample of 120 participants to evaluate the 
within-person reproducibility (Townsend et al. 
2013). The creatinine-adjusted intraclass cor-
relation coefficients (ICCs) between the two 
measurements were ≥ 0.30 for all metabolites 
[ranging from 0.30 for MiBP to 0.53 for MBP, 
except for MEHP and BPA (0.14 for both)].
Statistical methods. We summed molar 
concentrations of MEHP, MEHHP, 
MECPP, and MEOHP to represent total 
metabolites of di(2-ethylhexyl) phthalate 
(DEHP). Likewise, we summed molar con-
centrations of MBP and MiBP. We calcu-
lated total phthalate concentrations (in 
nanomoles per liter) as the summed values of 
MEHP, MEHHP, MECPP, MEOHP, MBP, 
MiBP, MBzP, and MEP to facilitate com-
parisons with previous studies. We calculated 
Spearman correlation coefficients (rS) among 
controls to evaluate the   intercorrelation 
among urinary metabolites.
Study participants were categorized into 
quartiles according to the cohort-specific 
distribution of metabolite concentrations 
among controls. We used conditional logistic 
regression to model the associations under 
investigation. We adjusted for body mass 
index (BMI; < 25.0 kg/m2, 25.0–27.4 kg/m2, 
27.5–29.9 kg/m2, 30.0–32.4 kg/m2, ≥ 32.5 kg/m2, 
missing category), smoking status (current 
smoker, past smoker, non  smoker), oral con-
traceptive use (never used, past user, current 
user; NHSII only), hormone replacement 
therapy (yes, no; NHS only), physical activ-
ity (METs-hr/week), alcohol use (abstainer, 
< 5.0 g/day, 5.0–14.9 g/day, ≥ 15.0 g/day), 
family history of diabetes (yes, no), history 
of hyper  cholesterolemia or hypertension 
(yes, no), AHEI score, and urinary creatinine Sun et al.
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(mg/dL). In the current analysis we used 
measurements of covariates derived from the 
questionnaire administered in 2000 (1998 
for AHEI and alcohol use) in NHS or 1995 
in NHSII. p-Values for linear trend were 
calculated by modeling the median value of 
each quartile as a continuous variable. We 
pooled   cohort-  specific estimates for the NHS 
and NHSII using a random-effects meta-
analysis. Heterogeneity of odds ratios (ORs) 
between the two cohorts was evaluated by the 
Cochrane Q statistic and the I2 statistic.
Restricted cubic spline regressions with 
3 knots were used to model potential dose–
response relations between the metabolites 
and diabetes (Durrleman and Simon 1989). 
In this analysis, to maximize statistical 
power, we pooled data for case–control pairs 
from the two cohorts and then performed 
statistical analyses using conditional logistic 
regression. In addition, participants in the 
top 5% of metabolite concentrations were 
excluded to minimize the potential impact 
of extreme outliers. We used likelihood ratio 
tests (LRTs) to examine nonlinearity, com-
paring the model with the linear term only 
to the model with the linear plus the cubic 
spline terms.
LRTs were also used to examine effect 
modification of associations between metabo-
lites and T2D by testing the significance of 
multiplicative interaction terms between 
metabolite quartiles modeled as ordinal varia-
bles and each potential modifier.
As secondary analyses, we calculated 
Spearman partial correlation coefficients 
Table 1. Characteristics of diabetes cases and controls in the NHS and NHSII at urinary sample collection.
Characteristica
NHS NHSII
Cases (n = 394) Controls (n = 393) p-Valueb Cases (n = 577) Controls (n = 577) p-Valueb
Age at urine sample collection (years)c 65.6 ± 6.4 65.6 ± 6.4 0.98 45.6 ± 4.4 45.6 ± 4.4 0.91
BMI (kg/m2)d 29.7 ± 5.8 26.0 ± 4.5 < 0.0001 33.5 ± 7.0 25.7 ± 5.5 < 0.0001
BMI categories (%) < 0.0001 < 0.0001
< 25.0 21.3 47.8 9.7 54.6
25.0–27.4 16.5 20.1 11.4 16.1
27.5–29.9 18.5 12.7 11.3 8.8
30.0–32.4 14.7 9.4 14.6 5.9
≥ 32.5 27.4 9.4 49.1 10.6
Missing 1.5 0.5 4.0 4.0
Physical activity (MET-hr/week) 16.8 ± 22.8 19.0 ± 20.9 0.15 17.0 ± 27.3 19.5 ± 22.9 0.09
Smoking status (%) 0.58 0.02
Current smoker 6.6 5.9 12.7 8.2
Former smoker 47.5 44.5 22.9 27.4
Never smoked 45.9 49.6 64.5 64.5
Alcohol intake (%) 0.01 0.0002
Abstainer 25.1 20.6 42.5 32.6
< 5.0 g/day 50.0 45.8 46.3 48.4
5.0–14.9 g/day 15.2 24.4 8.5 14.7
≥ 15.0 g/day 9.6 9.2 2.8 4.3
Hypertension (%) 61.9 40.0 < 0.0001 27.6 12.5 < 0.0001
Hypercholesterolemia (%) 73.4 59.5 < 0.0001 46.5 23.2 < 0.0001
White (%)c 97.7 98.2 0.62 95.7 96.5 0.45
Family history of diabetes (%) 38.8 27.5 0.0007 32.6 16.6 < 0.0001
Fasting ≥ 8 hr at blood sample collection (%)c 93.2 94.2 0.57 73.8 75.9 0.42
Menopause (%)c 100.0 99.2 0.25 34.7 34.7 > 0.99
Postmenopausal hormone use (%)c,e 59.1 62.1 0.40 49.0 49.0 > 0.99
Use of oral contraceptive (%)f — 0.05
Current user — — 2.3 4.9
Past user — — 84.2 83.4
Never used — — 13.5 11.8
Diet
Total energy (kcal/day) 1778.9 ± 415.4 1761.2 ± 402.0 0.54 1861.1 ± 513.2 1784.0 ± 485.7 0.009
Trans fats (% of energy) 1.63 ± 0.40 1.58 ± 0.40 0.07 1.61 ± 0.52 1.51 ± 0.49 0.0006
Polyunsaturated: saturated fat ratio 0.56 ± 0.12 0.58 ± 0.14 0.05 0.50 ± 0.12 0.52 ± 0.14 0.008
Coffee (cups/day) 2.0 ± 1.4 2.2 ± 1.5 0.09 1.3 ± 1.7 1.7 ± 1.7 0.0003
Whole grains (g/day) 18.6 ± 10.3 20.7 ± 10.0 0.004 19.6 ± 12.8 22.3 ± 14.4 0.0008
Fruits (servings/day) 2.2 ± 1 2.3 ± 1.0 0.07 1.8 ± 1.1 1.9 ± 1.3 0.01
Vegetables (servings/day) 3.2 ± 1.3 3.3 ± 1.4 0.24 2.8 ± 1.6 2.8 ± 1.8 0.85
Red meat (servings/day) 0.9 ± 0.4 0.8 ± 0.4 < 0.0001 0.9 ± 0.6 0.8 ± 0.6 < 0.0001
Fish (servings/day) 0.3 ± 0.2 0.3 ± 0.2 0.94 0.2 ± 0.2 0.2 ± 0.2 0.29
Soft drinks (servings/day) 0.8 ± 0.8 0.6 ± 0.7 0.0004 1.7 ± 1.5 1.2 ± 1.2 < 0.0001
AHEI scoreg 50.0 ± 8.2 52.7 ± 8.6 < 0.0001 46.7 ± 9.2 49.5 ± 9.8 < 0.0001
Urinary creatinine (mg/dL)h 66.6 (45.2, 101.6) 60.9 (43.0, 90.9) 0.05 87.8 (63.9, 127.1) 87.8 (61.5, 119.6) 0.25
Urinary BPA (μg/L)h 1.5 (1.0, 2.8) 1.5 (1.0, 2.7) 0.98 2.3 (1.4, 3.8) 2.0 (1.3, 3.5) 0.19
Urinary phthalate metabolites (nmol/L)h
DEHPi 277.6 (154.4, 545.8) 229.7 (142.8, 463.7) 0.05 324.7 (201.4, 586.3) 301.7 (170.8, 522.3) 0.02
Butyl phthalatesi 107.7 (70.8, 209.8) 114.8 (67.8, 212.0) 0.88 249.2 (151, 421.0) 248.5 (150.6, 378.4) 0.44
Total phthalatesi 1055.1 (616.1, 1885.3) 1049.6 (571.8, 2010.3) 0.87 1495.6 (900.8, 2876.6) 1479.5 (858.5, 2684.2) 0.32
aPlus-minus values are mean ± SD. Percentages are based on non-missing data. bp-Value estimates are based on Student’s t-test for variables expressed as mean ± SD, Wilcoxon 
rank–sum test for variables expressed as median (IQR), or Pearson χ2 test for variables expressed as percentages. cMenopausal status and hormone use were matching factors in the 
NHSII only. dBMI was missing for 8 participants in the NHS and 46 participants in the NHSII. eAmong menopausal women only. fAmong premenopausal women only. gMeasuring the 
overall diet quality by summarizing higher intakes of vegetables, fruits, nuts, soy, and cereal fiber, higher ratios of chicken plus fish to red meat and polyunsaturated to saturated fat, 
lower intake of trans fats, and multivitamin use of ≥ 5 years. hValues are median (25th percentile, 75th percentile). iDEHP metabolites included MEHP, MEHHP, MEOHP, and MECPP; 
butyl phthalate metabolites, MBP and MiBP; total phthalate metabolites, MEP, MEHP, MEHHP, MECPP, MEOHP, MBzP, MBP, and MiBP.BPA, phthalates, and diabetes
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between the chemicals and plasma levels of 
liver enzymes and fetuin-A, as well as their 
interactions on incident T2D, in the NHS 
to evaluate the potential adverse effects of 
the pollutants on liver function as suggested 
by animal experiments and human observa-
tional studies (Desvergne et al. 2009; Lang 
et al. 2008).
All p-values were two-sided and p < 0.05 
was considered statistical significance. Data 
were analyzed with SAS, version 9.2 (SAS 
Institute Inc., Cary, NC).
Results
Table 1 shows the characteristics of the cases 
and controls at sample collection. The NHS 
participants were, on average, 20 years older 
than the NHSII counterparts at urine sample 
collection. Differences in menopausal status 
are consistent with differences in age between 
the two cohorts. Urinary concentrations of 
BPA and phthalate metabolites were higher in 
NHSII participants than NHS participants. 
In both cohorts, cases had higher urinary 
concentrations of DEHP metabolites than 
controls, whereas the concentrations of other 
chemicals were similar.
Phthalate metabolites derived from the 
same parent chemicals were strongly corre-
lated with each other (rS = 0.59–0.91 among 
DEHP metabolites, or 0.98 between the two 
butyl phthalate metabolites), and correlations 
were weaker otherwise (see Supplemental 
Material, Table S1). BPA concentrations were 
correlated with some of the phthalate metabo-
lites, although the correlations were weak to 
moderate (rS ≤ 0.26).
Estimated associations between BPA con-
centrations and incident T2D are shown in 
Table 2. In both cohorts, BPA was not associ-
ated with T2D based on conditional logistic 
models that accounted for matching and were 
adjusted for creatinine levels only (model 1). 
In the NHS, further adjustment for covari-
ates (model 2), and additional adjustment for 
BMI (model 3), did not change associations 
with BPA materially. In contrast, in the 
NHSII, we estimated significant positive 
associations with T2D after adjustment 
for additional covariates, especially BMI 
(model 3; OR = 2.08; 95% CI: 1.17, 3.69; 
ptrend = 0.02).
We observed a similar pattern of divergent 
associations between two cohorts for summed 
DEHP, butyl, and total phthalate metabo-
lites (Table 3). In the NHSII, butyl phthalate 
and total phthalate metabolites were signifi-
cantly associated with T2D. After adjusting 
for confounders, especially BMI, ORs compar-
ing extreme quartiles for the butyl and total 
phthalate metabolites were 3.16 (95% CI: 
1.68, 5.95; ptrend = 0.0002) and 2.14 (95% CI: 
1.19, 3.85; ptrend = 0.02), respectively.
Analysis on joint associations between 
BPA and butyl phthalates in the NHSII 
showed that the effects of these two 
classes of compounds were multiplicative 
(pinteraction = 0.96) (see Supplemental Material, 
Figure S1). Furthermore, we did not observe 
any significant correlations between the 
chemicals and liver enzymes or fetuin-A levels 
measured in the NHS (rS ≤ 0.10), or any sig-
nificant effect modifications by liver enzymes 
on the associations between the pollutants and 
T2D risk (data not shown).
The associations between individual 
phthalate metabolites and incident T2D 
are presented in Supplemental Material, 
Table S2. In the NHSII, both individual 
butyl phthalate metabolites (MBP and 
MiBP) were positively associated with 
T2D. When cohort estimates were com-
bined, we observed significant associations 
for MECPP and phthalic acid (Figure 1); 
the pooled ORs comparing extreme quar-
tiles were 2.17 (95% CI: 1.40, 3.38; 
pheterogeneity = 0.79) and 1.70 (95% CI: 1.08, 
2.70; pheterogeneity = 0.84), respectively.
We conducted an ad hoc analysis to 
explore whether the positive associations of 
BPA and butyl phthalates in the NHSII were 
entirely due to the confounding by BMI. 
Specifically, we examined joint associations 
between BMI and BPA or butyl phthalate 
levels using conditional logistic regression 
with multivariate adjustment of all covariates 
except BMI. In general, within each BMI 
category, the highest BPA or butyl phthalate 
quartile tended to be associated with higher 
T2D risk in comparison with the lowest quar-
tile (Figure 2; pinteraction ≥ 0.64). Of note, par-
ticipants with missing BMI values (4%) were 
excluded from this analysis.
We explored age and age-related factors 
that may explain the heterogeneous associa-
tions of BPA between the two cohorts. Using 
combined data from both cohorts, we found 
that the association of BPA was stronger for 
diabetes cases occurred at a relatively younger 
age (≤ 55 years) than older cases (data not 
shown). Furthermore, the positive association 
between BPA and T2D risk was primarily 
ascribed to the menopausal status of the cases 
at time of diagnosis (Table 4). The ORs com-
paring highest versus lowest quartiles were 
5.83 (95% CI: 1.68, 20.19; ptrend = 0.01) 
for premenopausal cases and 0.83 (95% CI: 
0.54, 1.27; ptrend = 0.50) for postmenopausal 
cases (pinteraction = 0.03). Using the NHSII 
data only, we observed a similar pattern of 
associations, although the test for interaction 
was not significant: the corresponding ORs 
were 4.08 (95% CI: 1.39, 12.0; ptrend = 0.01) 
and 1.29 (95% CI: 0.62, 2.68; ptrend = 0.56), 
respectively. We did not observe the same 
interactions for phthalates (data not shown). 
We also explored whether the stronger asso-
ciations observed in the NHSII may be due to 
higher concentrations of the pollutants in this 
younger cohort by categorizing the NHSII 
participants using the cut points for making 
quartiles in the NHS. The associations did 
not change materially in this analysis (data 
not shown).
Figure 3 shows the dose–response relation 
between BPA and T2D. We observed a linear 
association among premenopausal cases only 
(ptrend = 0.02). Butyl phthalate metabolites 
Table 2. ORs (95% CIs) of incident T2D by quartiles of urinary concentrations (μg/L) of BPA: the NHS and NHSII.
Variable Quartile 1 (lowest) Quartile 2 Quartile 3 Quartile 4 (highest) ptrend
NHS/BPA
Median (range) 0.7 (0.03–1.0) 1.2 (1.0–1.5) 2.0 (1.5–2.7) 4.4 (2.8–56.1)
Case/control (n) 102/99 95/98 98/98 99/98
Model 1a 1 0.92 (0.62, 1.37) 0.85 (0.56, 1.29) 0.81 (0.52, 1.26) 0.40
Model 2b 1 0.99 (0.63, 1.54) 0.96 (0.60, 1.53) 0.77 (0.47, 1.26) 0.25
Model 3c 1 0.91 (0.56, 1.48) 0.98 (0.60, 1.61) 0.81 (0.48, 1.38) 0.45
NHSII/BPA
Median (range) 0.9 (0.03–1.3) 1.7 (1.3–2.0) 2.7 (2.0–3.5) 5.4 (3.5–45.4)
Case/control (n) 132/144 132/144 154/145 159/144
Model 1a 1 0.97 (0.69, 1.37) 1.09 (0.77, 1.54) 1.10 (0.76, 1.59) 0.54
Model 2b 1 1.08 (0.72, 1.61) 1.29 (0.86, 1.94) 1.40 (0.91, 2.15) 0.13
Model 3c 1 1.34 (0.70, 2.27) 1.91 (1.11, 3.29) 2.08 (1.17, 3.69) 0.02
aIn model 1, we automatically adjusted for matching factors, including age at urine sample collection, ethnicity, fasting status, and time of sample collection, menopausal status, and 
use of hormone replacement therapy (NHSII only), by using conditional logistic regression, and also for urinary creatinine levels. bBased on model 1, we adjusted model 2 for smok-
ing status, postmenopausal hormone use (NHS only), oral contraceptive use (NHSII only), physical activity, alcohol use, family history of diabetes, history of hypercholesterolemia or 
hypertension, and AHEI score. cBased on model 2, we adjusted model 3 for BMI.Sun et al.
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were monotonically associated with an 
increased T2D risk among all participants, 
especially for those at high-exposure levels 
(ptrend = 0.02; see Supplemental Material, 
Figure S2B). DEHP and total phthalates 
were not significantly associated with incident 
T2D in this analysis.
Discussion
In this prospective investigation among 
U.S. women, we found positive associations 
between urinary BPA and butyl phthalate 
concentrations and incident T2D in the 
NHSII participants, but not in the older 
NHS counterparts. The positive associations 
of BPA and phthalates with T2D were signifi-
cant only after adjusting for BMI, although 
in joint analyses without further adjustment 
for BMI, BPA and butyl phthalates were 
positively associated with T2D risk among 
participants across BMI categories, suggest-
ing that the positive associations may not be 
due entirely to the confounding by BMI. The 
distinct associations observed between the 
two cohorts could be due to differences in age 
distribution or menopausal status, although 
the role of chance cannot be excluded.
The majority of publications regarding 
associations of BPA/phthalates with T2D are 
analyses using the cross-sectional National 
Health and Nutrition Examination Survey 
(NHANES). Lang et al. (2008) reported a 
significant, positive association between 
urinary BPA concentrations and diabetes 
prevalence among 1,455 U.S. adults in the 
NHANES 2003–2004 cycle. Shankar and 
Teppala (2011) observed a similar association 
using data from NHANES 2003–2008 cycles, 
but an independent analysis by Silver et al. 
(2011) suggested this association was primar-
ily driven by data from the 2003–2004 cycle.
More recently, LaKind et al. (2012) found 
no associations in all NHANES cycles, prob-
ably owing to different exclusion criteria and 
model covariates. Data regarding phthalates 
were likewise exclusively from cross-sectional 
analyses, in which positive associations with 
T2D were documented for various phthal-
ate metabolites, including DEHP metabolites 
(Svensson et al. 2011), MBzP (James-Todd 
et al. 2012), MiBP (James-Todd et al. 2012; 
Lind et al. 2012a), and mono-methyl 
  phthalate (Lind et al. 2012a).
The mechanistic hypothesis underlying 
a link between BPA/phthalates and diabe-
tes risk is primarily derived from animal 
experiments. In vivo and in vitro experiments 
among rodent models have shown that BPA 
is a ubiquitous xenoestrogen that can acti-
vate estrogen receptors (ERs), as well as some 
novel ER-independent signaling pathways, 
even at physiologically relevant low doses 
(Lemmen et al. 2004; Quesada et al. 2002; 
Wozniak et al. 2005; Zsarnovszky et al. 
2005). ERs, especially ERα, when activated, 
regulate energy homeostasis through multi-
ple pathways, including glucose transport, 
insulin secretion, and other mechanisms 
(Chen et al. 2009; Nadal et al. 2009). ERs 
Table 3. ORs (95% CIs) of incident T2D by quartiles of urinary concentrations of phthalate metabolites (nmol/L): the NHS and NHSII.
Variable Quartile 1 (lowest) Quartile 2 Quartile 3 Quartile 4 (highest) ptrend
NHS
DEHPa
Median (range) 102.9 (1.5–142.8) 180.1 (142.8–229.7) 311.6 (231.8–463.7) 844.5 (464.5–27829.8)
Case/control (n) 88/98 79/99 104/98 123/98
Model 1b 1 0.85 (0.54, 1.32) 1.09 (0.71, 1.66) 1.27 (0.81, 1.99) 0.13
Model 2c 1 0.82 (0.50, 1.35) 1.06 (0.65, 1.72) 1.34 (0.80, 2.22) 0.10
Model 3d 1 0.88 (0.52, 1.50) 1.02 (0.61, 1.71) 1.34 (0.77, 2.30) 0.14
Butyl phthalatesa
Median (range) 47.1 (1.6–67.6) 88.7 (67.8–113.2) 152.0 (114.3–212.0) 334.2 (213.2–12702.7)
Case/control (n) 96/98 109/97 94/100 95/98
Model 1b 1 1.06 (0.69, 1.63) 0.80 (0.51, 1.26) 0.72 (0.43, 1.20) 0.15
Model 2c 1 1.20 (0.74, 1.96) 0.93 (0.56, 1.55) 0.94 (0.53, 1.68) 0.65
Model 3d 1 1.26 (0.75, 2.12) 1.01 (0.59, 1.73) 0.91 (0.50, 1.68) 0.51
Total phthalatesa
Median (range) 391.6 (11.0–571.4) 770.5 (571.8–1049.3) 1386.5 (1049.6–2010.3) 3824.1 (2010.6–49621.3)
Case/control (n) 89/98 107/98 105/99 93/98
Model 1b 1 1.13 (0.74, 1.71) 1.07 (0.70, 1.63) 0.86 (0.54, 1.38) 0.27
Model 2c 1 1.20 (0.75, 1.91) 1.07 (0.67, 1.71) 0.90 (0.53, 1.53) 0.36
Model 3d 1 1.20 (0.72, 1.99) 1.15 (0.70, 1.91) 0.87 (0.49, 1.53) 0.29
NHSII
DEHPa
Median (range) 123.2 (1.5–170.4) 223.0 (170.8–300.1) 376.8 (301.7–522.3) 869.7 (525.7–11707.2)
Case/control (n) 99/144 165/144 139/145 174/144
Model 1b 1 1.64 (1.16, 2.31) 1.36 (0.95, 1.96) 1.72 (1.16, 2.54) 0.08
Model 2c 1 1.67 (1.12, 2.49) 1.47 (0.96, 2.24) 1.89 (1.20, 2.98) 0.05
Model 3d 1 1.80 (1.07, 3.04) 1.62 (0.95, 2.76) 1.91 (1.04, 3.49) 0.20
Butyl phthalatesa
Median (range) 107.0 (1.6–150.4) 199.5 (150.6–248.0) 300.3 (248.5–378.4) 591.0 (379.3–29543.2)
Case/control (n) 144/144 144/144 112/145 177/144
Model 1b 1 0.95 (0.68, 1.35) 0.70 (0.48, 1.03) 1.08 (0.74, 1.60) 0.34
Model 2c 1 1.00 (0.67, 1.49) 0.82 (0.52, 1.27) 1.48 (0.94, 2.33) 0.03
Model 3d 1 1.38 (0.81, 2.35) 1.17 (0.66, 2.10) 3.16 (1.68, 5.95) 0.0002
Total phthalatesa
Median (range) 599.8 (11.0–858.5) 1104.2 (858.5–1462.9) 1878.2 (1479.5–2684.2) 4348.5 (2695.5–60068.1)
Case/control (n) 143/144 156/144 117/145 161/144
Model 1b 1 1.10 (0.79, 1.55) 0.89 (0.61, 1.29) 1.09 (0.75, 1.58) 0.64
Model 2c 1 1.25 (0.83, 1.89) 0.97 (0.62, 1.50) 1.27 (0.82, 1.96) 0.36
Model 3d 1 1.73 (1.01, 2.97) 1.08 (0.61, 1.92) 2.14 (1.19, 3.85) 0.02
aDEHP metabolites included MEHP, MEHHP, MEOHP, and MECPP; butyl phthalates, MBP and MiBP; total phthalates, MEP, MEHP, MEHHP, MECPP, MEOHP, MBzP, MBP, and MiBP. 
bIn model 1, we automatically adjusted for matching factors, including age at urine sample collection, ethnicity, fasting status, and time of sample collection, menopausal status, and 
use of hormone replacement therapy (NHSII only), by using conditional logistic regression, and also for urinary creatinine levels. cBased on model 1, we adjusted model 2 for smok-
ing status, postmenopausal hormone use (NHS only), oral contraceptive use (NHSII only), physical activity, alcohol use, family history of diabetes, history of hypercholesterolemia or 
hypertension, and AHEI score. dBased on model 2, we adjusted model 3 for BMI.BPA, phthalates, and diabetes
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are expressed in beta cells (Nadal et al. 2000), 
and, despite the low binding affinity of BPA 
to ERs in vitro (Kuiper et al. 1997), BPA and 
17β-estradiol (E2) can both stimulate insu-
lin biosynthesis and secretion by activating 
ERα with equal potency in mice (Alonso-
Magdalena et al. 2006, 2008; Ropero et al. 
2008). Administration of low-dose BPA or 
E2 (10 μg/kg) to adult mice led to chronic 
hyperinsulinemia, followed by insulin 
resistance (Alonso-Magdalena et al. 2006). 
Furthermore, BPA and E2 can also enhance 
insulin secretion by activating ERβ or 
ER-independent pathways in mouse mod-
els (Nadal et al. 2009; Soriano et al. 2012). 
Although these lines of evidence from 
animal experiments suggest interactive effects 
between BPA and estrogens, the extrapola-
tion of the evidence to humans is unclear. 
Therefore, the stronger association of BPA 
with T2D risk among younger women before 
menopause, although biologically plausible, 
may also be a chance finding and should be 
replicated in future studies. Effects of BPA 
exposures on adiponectin release, oxidative 
stress, dyslipidemia, and other diabetes risk 
factors are among other potential mecha-
nisms (Ben-Jonathan et al. 2009; Bindhumol 
et al. 2003; Hugo et al. 2008; Nakagawa and 
Tayama 2000).
Phthalates may result in increased dia-
betes risk through the activation of PPARs 
(Casals-Casas and Desvergne 2011), which 
are master regulators of lipid and glucose 
homeostasis (Evans et al. 2004). For exam-
ple, in vitro experiments have demonstrated 
that MEHP induces adipogenesis by activat-
ing PPAR-γ (Feige et al. 2007), although 
evidence from in vivo studies is not entirely 
consistent (Feige et al. 2010). Other possible 
pathways include adverse effects of DEHP 
exposures on thyroid hormones (Gayathri 
et al. 2004; Sugiyama et al. 2005) and glucose 
metabolism (Gayathri et al. 2004; Rengarajan 
et al. 2007). In vitro studies have also showed 
that butylbenzyl phthalate (BBP) and its 
monoester metabolites, such as MBP and 
MBzP, were able to activate PPAR subtypes, 
although their effects were weaker than those 
for MEHP (Corton and Lapinskas 2005; 
Lapinskas et al. 2005). Of note, because of 
the between-species differences in terms of 
metabolism and PPAR functionality, the rel-
evance of animal study evidence regarding 
phthalates and humans is unclear (Hauser 
and Calafat 2005). Although animal evidence 
may help explain the positive associations of 
phthalates observed in the NHSII, the lack 
of association in older women is not read-
ily explained. Further, whether individual 
phthalate metabolites have divergent or simi-
lar metabolic effects is largely unknown, and 
thus caution is needed when interpreting the 
positive associations for total phthalates.
The present study has several caveats that 
deserve discussion. Our study participants 
were exclusively registered female nurses who 
are not representative of the general popula-
tion, limiting the generaliza  bility of the results 
to men and other ethnic groups. However, 
the concentrations of BPA and phthalate 
metabolites in these nurses substantially over-
lapped with those observed in the NHANES 
(Calafat et al. 2008; Silva et al. 2004). The 
homogeneity of our cohort participants in 
terms of socioeconomic status and universal 
access to health care services actually reduces 
confounding and improves internal validity. 
An important limitation of the exposure mea-
surements is that the within-person stability 
Figure 1. Pooled ORs (95% CIs) of incident T2D comparing extreme quartiles of individual urinary concen-
trations of phthalate metabolites in the NHS and NHSII. We adjusted the conditional logistic regression 
model for matching factors, including age at urine sample collection, ethnicity, fasting status, and time 
of sample collection, menopausal status, and use of hormone replacement therapy (NHSII only), urinary 
creatinine levels, BMI, smoking status, postmenopausal hormone use (NHS only), oral contraceptive use 
(NHSII only), physical activity, alcohol use, family history of diabetes, history of hyper  cholesterol  emia or 
hypertension, and AHEI score.
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Figure 2. The associations of BPA and butyl phthalates with incident T2D by BMI at urine sample collec-
tion, the NHSII. (A) Joint associations between BPA and BMI; (B) joint associations between butyl phthal-
ates and BMI. Data were analyzed using conditional logistic regression to examine joint associations 
between the chemicals and BMI. We adjusted these analyses for matching factors, including age at urine 
sample collection, ethnicity, fasting status, and time of sample collection, menopausal status and use of 
hormone replacement therapy (NHSII only), urinary creatinine levels, smoking status, postmenopausal 
hormone use (NHS only), oral contraceptive use (NHSII only), physical activity, alcohol use, family history 
of diabetes, history of hypercholesterolemia or hypertension, and AHEI score.
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of BPA concentrations over 1–3 years was 
quite low (ICC = 0.14), suggesting that first 
morning urine samples may not represent 
long-term exposure levels. Ideally, multiple 
urine samples collected over an extended 
period should be used to assess long-term 
exposures (Snijder et al. 2013) or to evaluate 
changes of exposures over time, but this is 
often not practical in large-scale epidemio-
logic studies. Typically, large random within-
person variations and the random error of 
BPA measurements (as reflected by the rela-
tively high CV) tend to diminish the ability 
to detect a modest association (Rothman and 
Greenland 1998). Likewise, misclassification 
of self-reported diabetes status among con-
trols, if any, is likely to be random and thus 
may further attenuate the true association 
toward the null. In addition, the findings are 
also possibly due to chance, especially when 
divergent associations were observed in the 
two cohorts. In NHSII controls, we found 
an inverse cross-sectional relation between 
BPA and BMI, one the strongest risk factors 
for T2D. This correlation is inconsistent with 
the findings from the NHANES (Carwile 
and Michels 2011). This inverse correlation 
may explain the association between BPA and 
T2D after adjustment for BMI in the NHSII. 
However, adjustment for BMI minimally 
changed the associations between BPA and 
diabetes prevalence in the NHANES (Lang 
et al. 2008), and null associations of BPA 
with BMI were observed in another study 
(Melzer et al. 2012). Likewise, associations 
between phthalate metabolites and BMI were 
also inconsistent with the literature (Hatch 
et al. 2008; Lind et al. 2012a; Teitelbaum 
et al. 2012; Trasande et al. 2012). It is pos-
sible that dietary and lifestyle predictors of 
BPA and phthalate exposures may vary across 
populations (Braun et al. 2011; Buckley et al. 
2012; Geens et al. 2012), and the cross-
sectional correlations with BMI may vary 
accordingly. An alternate explanation for the 
differential associations observed between the 
two cohorts is that the measured pollutant 
concentrations may not capture the etiologi-
cally relevant exposure levels in critical time 
windows in the NHS because urine samples 
were collected at much older ages in that 
cohort. Last, the role of residual or unmea-
sured confounding cannot be excluded. 
Although we controlled for an array of covari-
ates, including diet quality, some known 
routes of BPA and phthalate exposures, such 
as canned food or beverage consumption, 
contact with certain medical devices, and use 
of certain medications or consumer prod-
ucts (Buckley et al. 2012; Geens et al. 2012; 
Kelley et al. 2012), were not captured in our 
cohorts. Furthermore, confounding by other 
correlated chemicals from the same sources 
cannot be excluded.
Conclusions
In this prospective study we found positive 
associations of urinary concentrations of BPA 
and certain phthalate metabolites with inci-
dent T2D among middle-aged U.S. female 
nurses, but not among their older counter-
parts. Although different distribution of age 
and menopausal status may underlie these 
divergent results, these observations may also 
be due to chance, residual confounding, or 
other biases. Therefore, our results need to 
be interpreted with caution, especially con-
sidering that a single urinary measurement of 
phthalate metabolites or BPA may not repre-
sent longer-term exposure. Clearly, our find-
ings should be replicated in future prospective 
studies, and the significance of these chemi-
cals in T2D prevention and risk prediction 
remains uncertain.
Figure 3. ORs (95% CIs) of incident T2D by urinary concentrations of BPA. (A) Among premenopausal diabetes cases and their matched controls; (B) among 
postmenopausal diabetes cases and their matched controls. Study participants with the highest 5% of BPA levels were excluded to minimize potential impact 
of outliers. We adjusted the multivariate conditional logistic regression models with restricted cubic splines for matching factors, including age at urine sample 
collection, ethnicity, fasting status, and time of sample collection, menopausal status and use of hormone replacement therapy (NHSII only), urinary creatinine 
levels, BMI, smoking status, postmenopausal hormone use (NHS only), oral contraceptive use (NHSII only), physical activity, alcohol use, family history of diabe-
tes, history of hypercholesterolemia or hypertension, and AHEI score. Solid lines are ORs and dashed lines are 95% CIs. The dotted vertical lines represent the 
cut points for the quartiles listed in Table 2.
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Table 4. ORs (95% CIs) of incident T2D by quartiles of urinary concentrations of BPA according to the menopausal status of cases: the NHS and NHSII.
Menopausal status at diabetes diagnosis Quartile 1 (lowest) Quartile 2 Quartile 3 Quartile 4 (highest) ptrend pinteraction
Premenopause
Case/control (n) 39/45 54/55 77/79 80/71
Model 1a 1.0 2.53 (0.82, 7.76) 3.39 (1.14, 10.09) 5.83 (1.68, 20.19) 0.01 0.03
Postmenopause
Case/control (n) 194/197 191/188 162/162 174/172
Model 1a 1.0 0.85 (0.59, 1.23) 0.85 (0.57, 1.27) 0.83 (0.54, 1.27) 0.50
aAdjusted for matching factors, BMI, smoking status, postmenopausal hormone use (NHS only), oral contraceptive use (NHSII only), physical activity, alcohol use, family history of dia-
betes, history of hypercholesterolemia or hypertension, urinary creatinine levels, and AHEI score.BPA, phthalates, and diabetes
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